ArticleNanoscale2015
Anti-HER2/neu peptide-conjugated iron oxide nanoparticles for targeted delivery of paclitaxel to breast cancer cells.
Article in Nanoscale, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 96 citations in OpenAlex.
- Peptide-Functionalized Iron Oxide Nanoparticles for Cancer Therapy: Targeting Strategies, Mechanisms, and Translational Opportunities.Molecules (Basel, Switzerland) · 2026Review
- Advances in nucleic acid therapeutics: structures, delivery systems, and future perspectives in cancer treatment.Clinical and experimental medicine · 2024Review
- Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account.International journal of molecular sciences · 2024Review
- Synthesis and characterization of a magnetic bacterial cellulose-chitosan nanocomposite and evaluation of its applicability for osteogenesis.BioImpacts : BI · 2024Article
- Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity.Pharmaceutics · 2023Review
- Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics.Nanomaterials (Basel, Switzerland) · 2023Review
- Review
- Metal-based nano-delivery platform for treating bone disease and regeneration.Frontiers in chemistry · 2022Review
- Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Review
- Polymer-Coated Magnetite Nanoparticles for Protein Immobilization.Materials (Basel, Switzerland) · 2021Review
- Magnetic Iron Oxide Nanoparticle (IONP) Synthesis to Applications: Present and Future.Materials (Basel, Switzerland) · 2020Review
- Curcumin Loaded Nanoliposomes Localization by Nanoscale Characterization.International journal of molecular sciences · 2020Article
- Polymethine Dye-Functionalized Nanoparticles for Targeting CML Stem Cells.Molecular therapy oncolytics · 2020Article
- Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.Scientific reports · 2020Article
- Salinomycin-Loaded Iron Oxide Nanoparticles for Glioblastoma Therapy.Nanomaterials (Basel, Switzerland) · 2020Article
- Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer.Journal of nanobiotechnology · 2020Article
- Nanoparticles Targeting STATs in Cancer Therapy.Cells · 2019Review
- Theranostic Nanoparticles for RNA-Based Cancer Treatment.Accounts of chemical research · 2019Review
- Nanoparticle-mediated targeted drug delivery for breast cancer treatment.Biochimica et biophysica acta. Reviews on cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Nanoparticles (NPs) for targeted therapy are required to have appropriate size, stability, drug loading and release profiles, and efficient targeting ligands. However, many of the existing NPs such as albumin, liposomes, polymers, gold NPs, etc. encounter size limit, toxicity and stability issues when loaded with drugs, fluorophores, and targeting ligands. Furthermore, antibodies are bulky and this can greatly affect the physicochemical properties of the NPs, whereas many small molecule-based targeting ligands lack specificity. Here, we report the utilization of biocompatible, biodegradable, small (∼30 nm) and stable iron oxide NPs (IONPs) for targeted delivery of paclitaxel (PTX) to HER2/neu positive breast cancer cells using an anti-HER2/neu peptide (AHNP) targeting ligand. We demonstrate the uniform size and high stability of these NPs in biological medium, their effective tumour targeting in live mice, as well as their efficient cellular targeting and selective killing in human HER2/neu-positive breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.